Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 with FOLFIRI + Bevacizumab in Metastatic Colorectal Cancer
NCT02641873Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin in colorectal cancer (CRC), sponsored by Sumitomo Pharma. Primary endpoints: Incidence of adverse events and serious adverse events at 12 months, Number of participants with Dose-limiting toxicities at 12 months and 2 more. Started Dec 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02641873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641873.